Anti-HBV Surface Antigen Monoclonal antibody, Clone C117M

Background Hepatitis D virus (HDV) infection is a major global health issue around the world. There are approximately 15-20 million individuals infected with HDV worldwide. HDV infection usually causes increased mortality compared with infection with hepatitis B virus (HBV) alone. However, testing for the detection of HDV is not widely available in Taiwan. Therefore, the General Biologicals Corporation (GB) HDV Ab kit was developed for detecting anti-HDV antibodies. Methods A total of 913 serum and 462 EDTA-treated plasma samples were obtained from HBsAg-positive individuals in three hospitals in Taiwan from June 2014 to November 2017. We used three commercially available ELISA kits, DiaPro HDV Ab, DiaSorin ETI-AB-DELTAK-2 and GB HDV Ab, which were utilized strictly according to the instructions of the manufacturers. Results A comparative study of the results from the GB HDV Ab kit and the other commercial ELISA kits (DiaPro and DiaSorin) was performed to determine their efficacy for anti-HDV detection. The results indicated that the sensitivity of the GB HDV Ab kit for serum and EDTA samples was 100% compared to that of the DiaPro and DiaSorin kits, whereas the specificity for serum and EDTA samples was 99.3 and 98.1%, respectively. In addition, the overall agreement of the results of the GB HDV Ab kit for the serum and EDTA samples was 99.3 and 98.3%, respectively. It is worth noting that the performance of the GB HDV Ab kit was not affected by interference from triglyceride, bilirubin, hemoglobin, or human anti-mouse antibody. The limit of detection of the GB HDV Ab kit is approximately 100-fold lower than that of the other two commercial kits. Conclusions The GB HDV Ab kit, which presented equivalent sensitivity and specificity compared to both certified anti-HDV kits, would be a suitable kit for HDV diagnosis in Taiwan.

The present study aims to investigate an up-to-date prevalence of Hepatitis B Virus (HBV) infection among a mix population of Peshawar, Khyber Pakhtunkhwa, Pakistan. This study highlighted the relationship between HBV, demographic, clinical parameters and the risk factors in patients with HBV. A total of 4,758 blood samples from the mixed population were collected including 2382 male 2376 females. All the samples were subjected to hepatitis B surface antigen Immuno-chromatographic test (ICT), HBsAg enzyme-linked immunosorbent assay and by Reverse transcription polymerase chain reaction for the existence of antibodies against HBV. It was observed that 307 (12.8%) out of the 2382 individuals harbored antibodies in their blood against HBV. Among the different age groups, the highest number of incidences of HBV antibodies was found in the 16-25 age groups (7.01%). ICT positive samples were further screened by nested polymerase chain reaction (PCR) to determine the existence of active HBV-DNA. It was investigated that 5.7% (2382) of the total population (4758) tested was positive, among which the female 15.4% (367) possessed antibodies in their blood against HBV. Our results showed a higher male percentage than that of the female. The total HBV prevalence was recorded at 4.5% in all populations comprising both male and female. It was concluded that the highest prevalence of HBV was found in male and female in the age group 16-25, and then followed by the age group that lies between 26-55.